UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Quick Stats
Apr 01, 202666.7
AI Score
BUY0.05
Volume Ratio
May 11, 2026
Next Earnings
10
+ve Days (30d)
20
-ve Days (30d)
URGN Stock Summary
Last updated Apr 01, 2026
URGN is currently trading at $18.86, positioned below its 200-day moving average of $19.6, suggesting bearish momentum. The stock has a 52-week range of $3.42 to $30.
Technical Analysis: The 50-day moving average stands at $19.79, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 50.951, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.004, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates URGN at 66.7/100 with a BUY recommendation.
URGN (UroGen Pharma Ltd. Ordinary Shares) Indicators
Last updated Apr 01, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 50.951 |
| CMF (20) | -0.004 |
| ROC (10) | 2.489 |
| ADX (14) | 20.814 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -0.634 |
| AROONOSC (14) | -64.286 |
| WILLAMS %R (14) | -11.111 |
| MFI (14) | 28.169 |
URGN Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
URGN Price vs Max Options Open Interest
URGN Max Change In Options Open Interest
URGN Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
URGN Daily Out of Money Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
URGN Daily In the Money Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
URGN Most Active Options by Volume(near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
UroGen Pharma Ltd. Ordinary Shares is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
URGN Moving Averages Analysis
URGN (UroGen Pharma Ltd. Ordinary Shares) Simple Moving Averages
Moving Averages are last updated Apr 01, 2026
| Days | MA |
|---|---|
| 10 | 17.83 |
| 20 | 18.48 |
| 30 | 19.19 |
| 50 | 19.79 |
| 100 | 21.59 |
| 200 | 19.6 |
URGN Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 875.3 million |
| Earnings/Share ($) | -3.19 |
| Net Proft Margin (%) | -1.3981 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -1.1663 |
| EPS Estimate Next Year ($) | 0.9225 |
| WallStreet Target Price ($) | 35.625 |
| Most Recent Quarter |